$-0.22 EPS Expected for Soligenix, Inc. (SNGX)

March 15, 2018 - By Stephen Andrade

 $ 0.22 EPS Expected for Soligenix, Inc. (SNGX)

Analysts expect Soligenix, Inc. (NASDAQ:SNGX) to report $-0.22 EPS on March, 26.They anticipate $0.05 EPS change or 29.41 % from last quarter’s $-0.17 EPS. After having $-0.17 EPS previously, Soligenix, Inc.’s analysts see 29.41 % EPS growth. It closed at $2.01 lastly. It is down 63.52% since March 15, 2017 and is downtrending. It has underperformed by 80.22% the S&P500.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company has market cap of $17.55 million. It operates through two divisions, BioTherapeutics and Vaccines/BioDefense. It currently has negative earnings. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis.

More notable recent Soligenix, Inc. (NASDAQ:SNGX) news were published by: Prnewswire.com which released: “Soligenix to Present at the 12th Annual International Partnering Conference …” on March 13, 2018, also Twst.com with their article: “Interview with the Chairman, President & CEO: Soligenix, Inc. (NASDAQ:SNGX)” published on March 08, 2018, Prnewswire.com published: “Soligenix Announces Reverse-Split in Preparation for Proposed Up-Listing of …” on October 07, 2016. More interesting news about Soligenix, Inc. (NASDAQ:SNGX) were released by: Prnewswire.com and their article: “Soligenix Announces Recent Accomplishments And Year-End 2017 Financial Results” published on March 15, 2018 as well as Globenewswire.com‘s news article titled: “Soligenix, Inc. (Nasdaq: SNGX) to Ring The Nasdaq Stock Market Closing Bell” with publication date: August 30, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.